Short answer
Allogene Therapeutics, Inc. (ALLO) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $4M with net income of −$43M.
Q2 2026 key financials · XBRL
- Revenue
- $4M
- +380.0% QoQ
- Net income
- −$43M
- +16.2% YoY · −0.2% QoQ
- Operating margin
- -1221.9%
- EPS (diluted)
- −$0.12
- +47.8% YoY · +33.3% QoQ
Source: XBRL data from the Allogene Therapeutics, Inc. (ALLO) Q2 2026 10-Q on SEC EDGAR. USD.
Allogene Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Net loss $42.7M for Q2 2026; accumulated deficit $2.1B as of June 30, 2026
- ALLO-316 best reported response: 25.0% ORR overall, 31.3% in CD70-high patients
- Cash and investments $423.6M; April 2026 public offering extended runway into Q1 2029
- Continued net losses expected; R&D and G&A expenses expected to increase
Risk Factors
- Newly triggered risk: ALPHA3’s interim futility analysis covered only 24 randomized patients, limiting predictability of primary-endpoint success
- Clinical development risk: FCA-arm termination in ALPHA3 required protocol amendment, adding costs and potentially delaying timelines
- Regulatory risk: ALPHA3 approval may require pairing cema-cel with Foresight Diagnostics’ Clarity MRD companion diagnostic
- Operational risk: Expanding ALPHA3 internationally increases logistical and timing risks for MRD sample testing
- Financial risk: Cash and investments totaled $423.6 million at June 30, 2026, against a $2.1 billion accumulated deficit
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Allogene Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.